SummaryTNF-alpha and LT-alpha are involved in the pathogenesis of established lymphoproliferative diseases. Both molecules bind to TNFRI and TNFRII. TNFRI is the major mediator of the TNF pro-apoptotic and proliferative effects and TNFRII might enhance these effects. TNF receptors I and II are normally present on hematopoetic cells. TNFR II is characteristic only on immune cells, especially on peripheral leukocytes. Neoplastic B cells and activated B lymphocytes have increased expression of surface TNFR I. In this study, we have analyzed polymorphisms in the TNFRI gene (TNFRI+36A/G SNP) and polymorphism in the TNFRII gene (TNFRII + 676 T/G). All these polymorphisms were studied in patients with chronic lymphocytic leukemia (CLL), patients with non-Hodkin’s lymphoma (NHL) and in healthy controls. The present study was undertaken to investigate the genetic association of these polymorphisms with lymproproliferative disease development.A total of 68 patients (49-CLL, 19-HNL) were diagnosed at the Clinic of Hematology, Clinical centre Niš, Serbia, using clinical findings and conventional morphological, cytochemical and immunological tests. Genomic DNA was isolated from isolated lymphocytes by proteinase K/phenol/chloroform method, and genotyped for TNFR I (A36G) and TNFR II (T676G) using the PCR-RFLP method.No significant differences in allele frequencies of TNFR1 polymorphism were found between the patients with lymphoproliferative disease and healthy individuals. In a group of healthy individuals, the study has revealed for the first time significantly higher TNFRI G/G genotype compared to the patients with lymphoproliferative disease (χ22 = 5.66; p = 0.017). Also, we reported the implication of TNFRII T allele in NHL pathogenesis, respectively (χ22 = 10.77; p = 0.001; Mantel-Haenszel: χ22 = 10.64; p = 0.0011).Our data showed that TNFRII T676G polymorphisms have an important role in NHL pathogenesis but not in CLL patients. A/A polymorphism in TNFRI was not associated with CLL and NHL patients in the Serbian population. Investigated polymorphisms on TNFR genes in leukemic cells of CLL and NHL patients have not showed a correlation with increased proliferation of B lymphocytes and increased expression of TNF R II on B CLL lymphocytes.
References
1.
Al‐Ansari AS, Ollier WER, Villarreal J, Ordi J, Teh L ‐S., Hajeer AH. Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens. 2000;55(1):97–9.
2.
NIELÄNDER I, BUG S, RICHTER J, GIEFING M, IGNACIO MARTÍN‐SUBERO J, SIEBERT R. Combining array‐based approaches for the identification of candidate tumor suppressor loci in mature lymphoid neoplasms. APMIS. 2007;115(10):1107–34.
3.
Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica. 2007;92(7):960–9.
4.
Glenn CL. Linkage and association of tumor necrosis factor receptor 2 locus with hypertension, hypercholesterolemia and plasma shed receptor. Human Molecular Genetics. 2000;9(13):1943–9.
5.
Han X, Li Y, Huang J, Zhang Y, Holford T, Lan Q, et al. Identification of Predictive Pathways for Non-Hodgkin Lymphoma Prognosis. Cancer Informatics. 2010;9:CIN.S6315.
6.
Kim H, Chun S, Ku SY, Suh CS, Choi YM, Kim JG. Association between polymorphisms in tumor necrosis factor (TNF) and TNF receptor genes and circulating TNF, soluble TNF receptor levels, and bone mineral density in postmenopausal Korean women. Menopause. 2009;16(5):1014–20.
7.
Nishimura K, Tanuma S. Presence of DNase γ-Like Endonuclease in Nuclei of Neuronal Differentiated PC12 Cells. Apoptosis. 1998;3(2):97–103.
8.
Watts TH. TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES. Annual Review of Immunology. 2005;23(1):23–68.
9.
Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. International Journal of Cancer. 2009;124(7):1497–502.
10.
Glossop JR, Dawes PT, Nixon NB, Mattey DL. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Research & Therapy. 7(6).
11.
Szymanowska N, Klapper W, Gesk S, Küppers R, Martín-Subero JI, Siebert R. BCL2 and BCL3 are recurrent translocation partners of the IGH locus. Cancer Genetics and Cytogenetics. 2008;186(2):110–4.
12.
Bojarska-Junak A, Hus I, Szczepanek EW, Dmoszyńska A, Roliński J. Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leukemia Research. 2008;32(2):225–33.
13.
Fernández-Real JM, Vendrell J, Ricart W, Broch M, Gutiérrez C, Casamitjana R, et al. Polymorphism of the tumor necrosis factor-alpha receptor 2 gene is associated with obesity, leptin levels, and insulin resistance in young subjects and diet-treated type 2 diabetic patients. Diabetes Care. 2000;23(6):831–7.
14.
Waschke KA, Villani AC, Vermeire S, Dufresne L, Chen TC, Bitton A, et al. Tumor Necrosis Factor Receptor Gene Polymorphisms in Crohn’s Disease: Association with Clinical Phenotypes. The American Journal of Gastroenterology. 2005;100(5):1126–33.
15.
Geurts JMW. Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Human Molecular Genetics. 2000;9(14):2067–74.
16.
Mavri A, Bastelica D, Poggi M, Morange P, Peiretti F, Verdier M, et al. Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women. Thrombosis and Haemostasis. 2007;97(01):62–6.
17.
Plati J, Bucur O, Khosravi‐Far R. Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. Journal of Cellular Biochemistry. 2008;104(4):1124–49.
18.
Jevtovic-Stoimenov T, Kocic G, Pavlovic D, MaČukanovic-Golubović L, Marjanovic G, Djordjevic V, et al. Polymorphisms of tumor-necrosis factor-α−308 and lymphotoxin-α + 250: Possible modulation of susceptibility to apoptosis in chronic lymphocytic leukemia and non-Hodgkin lymphoma mononuclear cells. Leukemia & Lymphoma. 2008;49(11):2163–9.
19.
Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007;92(9):1242–5.
20.
Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, de Sanjose S, Hughes AM, et al. Tumor Necrosis Factor (TNF) and Lymphotoxin- (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium. American Journal of Epidemiology. 2010;171(3):267–76.
21.
Cerhan JR, Novak AJ, Fredericksen ZS, Wang AH, Liebow M, Call TG, et al. Risk of non‐Hodgkin lymphoma in association with germline variation in complement genes. British Journal of Haematology. 2009;145(5):614–23.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
